Evaluation of the long-term cost-effectiveness of once-weekly semaglutide vs dulaglutide for the treatment of type 2 diabetes mellitus in the UK

Using the IQVIA CORE Diabetes Model (version 9.0), researchers evaluated the long-term cost-effectiveness of semaglutide 0.5 mg and 1 mg vs dulaglutide 1.5 mg (two once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists) from a UK healthcare payer https://www.mdlinx.com/journal-summaries/semaglutide-dulaglutide-type-2-diabetes-mellitus/2018/10/29/7547918?spec=endocrinology&rcid=12